SCHEMBL3489276

SCHEMBL3489276

CCCCCCCCCCN1C(=O)N(Cc2ccccc2)c2cc(Cl)cc(N3CCNCC3)c2S1(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 4/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 1/20 0.37
KDM4E B2RXH2 3/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 3/20 0.36
DPP4 P27487 2/20 0.36
USP2 O75604 1/20 0.35
POLB P06746 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
EGFR P00533 1/20 0.35
HTR1A P08908 2/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
DRD3 P35462 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3488986 0.93 HTR6 (0.41) HTR6KDM4EMAPTDPP4EGFR
SCHEMBL3488912 0.92 MAPT (0.43) HTR6MEN1KMT2AALDH1A1KDM4E
SCHEMBL3489081 0.92 MAPT (0.43) HTR6MEN1KMT2AALDH1A1KDM4E
SCHEMBL3489119 0.89 HTR6 (0.43) HTR6MAPTDPP4EGFRHTR1A
SCHEMBL3488615 0.88 MAPT (0.44) HTR6MEN1KMT2AALDH1A1KDM4E
SCHEMBL3489858 0.88 HTR6 (0.45) HTR6MAPTDPP4EGFRHTR1A
SCHEMBL3488596 0.87 HTR6 (0.38) HTR6MEN1KMT2AALDH1A1MAPT
SCHEMBL3488509 0.85 MAPT (0.40) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL3490753 0.85 MAPT (0.40) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL3489620 0.84 MAPT (0.46) KMT2AALDH1A1KDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US claimed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D HTR6 2/4885MEN1 4200/4885KMT2A 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.